PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript April 25, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.2, expectations were $-1.31. PTC Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank […]
Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.